www.praktickelekarenstvi.cz e36 PRAKTICKÉ LÉKÁRENSTVÍ AKTUÁLNÍ FARMAKOTERAPIE Současná farmakoterapie benigní hyperplazie prostaty dle doporučení EAU ncbi.nlm.nih.gov/pubmed/18082216. 10. Roehrborn CG, et al. The effects of combination therapy with dutasteride and tamsu‑ losin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57: 123. https://www.ncbi.nlm.nih.gov/pu‑ bmed/19825505. 11. Karavitakis M, et al. Management of Urinary Retention in Patients with Benign Prostatic Obstruction: A Systematic Review and Meta-analysis. Eur Urol 2019; 75: 788. https://www. ncbi.nlm.nih.gov/pubmed/30773327. 12.Welk B, et al. The risk of fall and fracture with the initiation of a prostate-selective alpha antagonist: a population based cohort study. BMJ 2015; 351: h5398. https://www.ncbi.nlm. nih.gov/pubmed/26502947. 13. Van Dijk MM, et al. Effects of alpha(1)-adrenoceptor antagonists on male sexual functi‑ on. Drugs 2006; 66: 287. https://www.ncbi.nlm.nih.gov/pubmed/16526818. 14. Gacci M, et al. Impact of medical treatments for male lower urinary tract symptoms due to Benign prostatic hyperplasia on ejaculatory function: a systematic review and me‑ ta-analysis. J Sex Med 2014; 11: 1554. https://www.ncbi.nlm.nih.gov/pubmed/24708055. 15. Andriole G, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5al‑ phareductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004; 172: 1399. https://www.ncbi.nlm.nih.gov/pubmed/15371854. 16. Naslund MJ, et al. A review of the clinical efficacy and safety of 5alpha-reductase inhi‑ bitors for The enlarged prostate. Clin Ther 2007; 29: 17. https://www.ncbi.nlm.nih.gov/pu‑ bmed/17379044. 17. McConnell JD, et al. The effect of finasteride on the risk of acute urinary retention and the Need for surgical treatment among men with benign prostatic hyperplasia. Finasteri‑ de Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338: 557. https://www. ncbi.nlm.nih.gov/pubmed/9475762. 18. Nickel JC, et al. Comparison of dutasteride and finasteride for treating benign Prosta‑ tic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int 2011; 108: 388. https://www.ncbi.nlm.nih.gov/pubmed/21631695. 19. Boyle P, et al. Prostate volume predicts outcome of treatment of benign prostatic hy‑ perplasia With finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398. https://www.ncbi.nlm.nih.gov/pubmed/8804493. 20. Gittelman M, et al. Dutasteride improves objective and subjective disease measures in men With benign prostatic hyperplasia and modest or severe prostate enlargement. J Urol 2006; 176: 1045. https://www.ncbi.nlm.nih.gov/pubmed/16890688. 21. Roehrborn CG, et al. Long-term sustained improvement in symptoms of benign Pro‑ static hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies. BJU Int 2005; 96: 572. https://www.ncbi.nlm.nih.gov/pubmed/16104912. 22. Roehrborn CG. BPH progression: concept and key learning fromMTOPS, ALTESS, COM‑ BAT, and ALF-ONE. BJU Int 2008; 101(Suppl. 3): 17. https://www.ncbi.nlm.nih.gov/pub‑ med/18307681. 23. Andriole GL, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010. 362: 1192. https://www.ncbi.nlm.nih.gov/pubmed/20357281. 24. Thompson IM, et al. The influence of finasteride on the development of prostate can‑ cer. N Engl J Med 2003; 349: 215. https://www.ncbi.nlm.nih.gov/pubmed/12824459. 25. Baldwin CM, et al. Transdermal oxybutynin. Drugs, 2009; 69: 327. https://www.ncbi.nlm. nih.gov/pubmed/19275276. 26. Michel MC, et al. Does gender or age affect the efficacy and safety of tolterodine? J Urol 2002; 168: 1027. https://www.ncbi.nlm.nih.gov/pubmed/12187215. 27. Hofner K, et al. Safety and efficacy of tolterodine extended release in men with ove‑ ractive Bladder symptoms and presumed non-obstructive benign prostatic hyperplasia. World J Urol 2007; 25: 627. https://www.ncbi.nlm.nih.gov/pubmed/17906864. 28. Kaplan SA, et al. Tolterodine extended release attenuates lower urinary tract symp‑ toms in Men with benign prostatic hyperplasia. J Urol 2005; 174: 2273. https://www.ncbi. nlm.nih.gov/pubmed/16280803. 29. Roehrborn CG, et al. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology 2008; 72: 1061. htt‑ ps://www.ncbi.nlm.nih.gov/pubmed/18817961. 30. Gacci M, et al. A systematic review and meta-analysis on the use of phosphodiestera‑ se 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symp‑ toms due to benign prostatic hyperplasia. Eur Urol 2012; 61: 994. https://www.ncbi.nlm. nih.gov/pubmed/22405510. 31. Wang Y, et al. Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis. Lower urinary tract symp‑ toms 2018. 10: 84. https://www.ncbi.nlm.nih.gov/pubmed/293415. 32. Porst H, et al. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract Symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. Urology 2013; 82: 667. https://www.ncbi.nlm.nih.gov/pubmed/23876588. 33. Casabe A, et al. Efficacy and safety of the coadministration of tadalafil once daily with Finasteride for 6 months in men with lower urinary tract symptoms and prostatic Enlarge‑ ment secondary to benign prostatic hyperplasia. J Urol 2014; 191: 727. https://www.ncbi. nlm.nih.gov/pubmed/24096118. 34. Andersson KE. On the Site and Mechanism of Action of beta3-Adrenoceptor Agonists in
RkJQdWJsaXNoZXIy NDA4Mjc=